Topical ibuprofen decreases early postburn edema.
We determined the effect of topically applied ibuprofen on formation of second-degree burn edema and prostanoid production, a possible causative factor. Six adult sheep were given second-degree burns on both flanks with water at 80 degrees C while they were under general anesthesia. Lymph (QL), draining the flank areas, was used to monitor edema formation and prostanoid production. A 5% ibuprofen cream was applied at 2 and 5 hours after the burn and full-thickness biopsy specimens of burned hide were obtained at 8 hours for determination of water content. The QL increased sixfold in nontreated and 2.5 times in treated burn tissue. The lymph/plasma (L/P) protein ratio increased from 0.4 to 0.58 in both sides. Lymph TxB2 was increased from baseline of 200 pg/ml to 500 +/- 100 and 310 +/- 90 pg/ml in untreated and treated sides, respectively. Lymph 6-keto-PGF1 alpha increased from a baseline of 50 +/- 10 to 150 +/- 40 and 90 +/- 80 pg/ml in untreated and treated sides. The difference between PG content of lymph in treated and untreated sides was significant. Plasma prostanoids, except for a transient early rise, remained at preburn baseline. Lymph ibuprofen content on the treated side rose to 1.9 +/- 0.8 mcg/ml with no detectable plasma level. Water content of hide increased from a control value of 74 +/- 2% to 84 +/- 2% in untreated burn, while the value in the treated side was 76 +/- 4%, a significant difference between the two sides. We conclude that topically applied ibuprofen decreases both local edema and prostanoid production in burn tissue without altering systemic production.
Demling
R H
RH
Longwood Area Trauma Center at Brigham and Women's Hospital, Boston, Mass. 02115.
Lalonde
C
C
D015121:6-Ketoprostaglandin F1 alpha / Q000032:analysis; D000287:Administration, Topical; D000818:Animals; D002056:Burns / Q000150:complications*; D004487:Edema / Q000209:etiology / Q000517:prevention & control*; D007052:Ibuprofen / Q000008:administration & dosage* / Q000032:analysis / Q000494:pharmacology; D008196:Lymph / Q000032:analysis; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D011453:Prostaglandins / Q000032:analysis; D012756:Sheep; D013929:Thromboxane B2 / Q000032:analysis
D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D007052:Ibuprofen